Verona Pharma's shares fall as higher R&D costs widen FY loss
3rd Jun 2016 12:52
(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its
Read moreVerona Pharma excites with asthma trial results
15th Mar 2016 10:35
(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu
Read moreVerona Pharma rallies on positive drug study results
29th Sep 2015 09:18
(ShareCast News) - Shares in Verona Pharma rallied after it announced positive headline data from the third and final part of a clinical study on its RPL554 drug for the treatment of chronic obstructive pulmonary disease. The drug development company said the primary objective of this part of the st
Read moreVerona Pharma plunges as interim loss widens
8th Sep 2015 08:28
(ShareCast News) - Shares in Verona Pharma plunged over 12% early on Tuesday, after the pharmaceutical company posted a wider interim pre-tax loss. The London-listed company, which attributed the wider loss to an increase in research and development spending, saw its pre-tax loss for the six months
Read moreVerona Pharma to launch secondary listing in Germany
12th Jun 2015 09:46
AIM-listed drug developer Verona Pharma has carried out a second listing in Germany. The move will be a way of further raising its profile within continental Europe and to increase the potential for investors in German-speaking Europe to trade in the company's shares, it said. The group will be lis
Read moreVerona Pharma's loss widens on extended development costs
12th May 2015 16:22
Verona Pharma posted a widened pre-tax loss for 2014 in the run up to its lead compound's commercial development. The company posted a pre-tax loss of £3.8m for 2014, up from £2.8m a year earlier, as research costs swelled from £1.7m to £2.6m over the period. Development bore a new commercial formu
Read moreVerona Pharma chairman increases stake
14th Jan 2015 15:05
The chairman of Verona Pharma increased his stake in the company following Monday's news that the biotechnology firm has dosed its first group of volunteers in its asthma trial. David Ebsworth showed confidence in the future of the business by purchasing 803,107 shares for 1.35p each, spending a tot
Read moreVerona Pharma doses first volunteers in 'RPL554' asthma trial
12th Jan 2015 11:55
Verona Pharma said the first group of volunteers have been dosed with its new nebulised formulation of its RPL554 product as part of a Phase I/II clinical trial, which analysts said was a significant step. The AIM company said the study's main objective was to confirm the safety, tolerability and br
Read moreFriday broker round-up UPDATE
7th Mar 2014 09:39
AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re
Read moreMonday broker round-up UPDATE
11th Nov 2013 08:50
Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin
Read moreVerona Pharma replaces CFO Lowe with Bungay
5th Sep 2013 08:15
Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.
Read moreSABMilller Chairman sells over 11m pounds in shares
23rd Jul 2013 16:21
Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so
Read moreAdvanced Oncotherapy CEO makes triple purchase
26th Apr 2013 15:09
The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p
Read moreAZ Electronic Materials directors try to minimize damage
10th Apr 2013 16:27
John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta
Read moreSmall caps round-up: Verona, Image Scan, Avia
4th Sep 2012 08:58
Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra
Read more